BSX
Boston Scientific Corp
NYSE: BSX · HEALTHCARE · MEDICAL DEVICES
$46.91
-0.55% today
Updated 2026-06-12
Market cap
$70.87B
P/E ratio
19.95
P/S ratio
3.44x
EPS (TTM)
$2.39
Dividend yield
—
52W range
$47 – $110
Volume
20.4M
Boston Scientific Corp (BSX) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed BSX price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$46.91
Today
Analyst consensus
$104.48
+122.72% · 12M
2030 Base
—
— future
NPV today
—
@ — WACC
21 analysts:
12 Buy4 Hold0 Sell
Management guidance
No specific CEO revenue targets found in provided data. Most recent guidance embedded in analyst consensus: FY2026 revenue of $22.49B (12.0% growth), FY2027 revenue of $24.83B (10.4% growth). Company has not publicly issued guidance beyond 2027.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
BSX · Boston Scientific Corp · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
—
NPV today: —
Base case (2030)
—
NPV today: —
Bull case (2030)
—
NPV today: —
WallStSmart.com
BSX financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $20.1B | $22.5B | $24.8B | $27.3B | $29.8B | $32.2B |
| Revenue growth | 19.9% | 12.0% | 10.4% | 9.9% | 8.9% | 8.3% |
| Net margin | — | — | — | — | — | — |
| EPS | $3.05 | $3.50 | $3.96 | $4.48 | $4.92 | $5.35 |
| Diluted shares | — | — | — | — | — | — |
| Net debt | — | — | — | — | — | — |
| P/S multiple | — | 2.0x | 2.0x | 2.0x | 2.0x | 2.0x |
| Implied price (base) | — | $182.18 | $201.02 | $226.15 | $245.00 | $263.84 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $32.2B | $32.2B | $32.2B |
| P/S multiple | 1.0x | 2.0x | 4.0x |
| Diluted shares | 0M | 0M | 0M |
| Net debt | — | — | — |
| Implied P/E † | — | — | — |
| 2030 Price | $— | $— | $— |
| NPV @ — | $— | $— | $— |
† Implied P/E: Multiples remain elevated across all three scenarios because BSX is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $— base case
BSX catalysts and risks
Growth catalysts
+ CHAMPION-AF trial success for WATCHMAN FLX device (met all primary/secondary endpoints)
+ HI-PEITHO trial showing EKOS Endovascular System superiority for acute pulmonary embolism
+ Farapulse label expansion in Europe (approved March 2026)
+ Electrophysiology segment recovery post-2026 weakness
+ Continued M&A and strategic acquisitions driving portfolio expansion
Key risks
- U.S. Electrophysiology segment facing competitive headwinds and market share loss (core growth driver under pressure)
- Multiple class action lawsuits alleging misrepresentation of EP growth sustainability and revenue guidance (July 2025-Feb 2026 period)
- Recent stock decline of 34%+ YTD and 42% from 52-week high indicates significant investor loss of confidence
- Q4 2025 results disappointed expectations; near-term growth deceleration acknowledged
- Valuation concern: Current P/E of 32x significantly above forward P/E of 16x suggests market pricing in major slowdown
Methodology · Boston Scientific Corp 2030 stock forecast model
Boston Scientific Corp 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 21 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (-100% cumulative for BSX by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory (— by 2030) |
| 3. Time value | NPV calculated using — WACC (sector fallback) |
| 4. Multiple framework | P/S compresses with scale: bear 1.0x / base 2.0x / bull 4.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.
BSX price target FAQ
How is the Boston Scientific Corp 2030 stock forecast calculated?
The BSX 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
What is the analyst consensus on BSX stock?
21 analysts cover BSX with an average 12-month price target of $104.48. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.